WO2012068076A3 - Formulations pharmaceutiques contenant des médicaments solubles - Google Patents

Formulations pharmaceutiques contenant des médicaments solubles Download PDF

Info

Publication number
WO2012068076A3
WO2012068076A3 PCT/US2011/060742 US2011060742W WO2012068076A3 WO 2012068076 A3 WO2012068076 A3 WO 2012068076A3 US 2011060742 W US2011060742 W US 2011060742W WO 2012068076 A3 WO2012068076 A3 WO 2012068076A3
Authority
WO
WIPO (PCT)
Prior art keywords
soluble drugs
pharmaceutical formulations
formulations containing
containing soluble
disintegrant
Prior art date
Application number
PCT/US2011/060742
Other languages
English (en)
Other versions
WO2012068076A2 (fr
Inventor
Sanjay Chhagan Wagh
Suryakumar Jayanthi
Sabyasachi Banerjee
Original Assignee
Dr. Reddy's Laboratories Ltd.
Dr. Reddy's Laboratories, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr. Reddy's Laboratories Ltd., Dr. Reddy's Laboratories, Inc. filed Critical Dr. Reddy's Laboratories Ltd.
Publication of WO2012068076A2 publication Critical patent/WO2012068076A2/fr
Publication of WO2012068076A3 publication Critical patent/WO2012068076A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne des compositions pharmaceutiques à libération modifiée de médicaments solubles dans l'eau. Dans des mode de réalisation, un médicament, une substance de régulation de la vitesse de libération hydrophile, et un désintégrant sont conjointement réduits en granules qui sont utilisés pour préparer des formes de dosage en comprimés ou en capsules.
PCT/US2011/060742 2010-11-15 2011-11-15 Formulations pharmaceutiques contenant des médicaments solubles WO2012068076A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN3428CH2010 2010-11-15
IN3428/CHE/2010 2010-11-15
US201161430589P 2011-01-07 2011-01-07
US61/430,589 2011-01-07

Publications (2)

Publication Number Publication Date
WO2012068076A2 WO2012068076A2 (fr) 2012-05-24
WO2012068076A3 true WO2012068076A3 (fr) 2012-08-02

Family

ID=46084600

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/060742 WO2012068076A2 (fr) 2010-11-15 2011-11-15 Formulations pharmaceutiques contenant des médicaments solubles

Country Status (1)

Country Link
WO (1) WO2012068076A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016088041A1 (fr) * 2014-12-01 2016-06-09 Sun Pharmaceutical Industries Limited Composition de cefpodoxime proxétil à libération prolongée
EP3694488A4 (fr) * 2017-10-13 2021-07-07 Research Triangle Institute Formulations de sulfate d'hydroxychloroquine et leurs procédés de préparation et d'utilisation
CN112176011B (zh) * 2020-10-26 2022-10-18 辰欣药业股份有限公司 一种酶催化制备盐酸伐昔洛韦的方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5602182A (en) * 1995-01-30 1997-02-11 American Home Products Corporation Taste masking pseudoephedrine HCL containing liquids
US20030190351A1 (en) * 2002-03-28 2003-10-09 Synthon Bv Extended release venlafaxine formulations
US6703044B1 (en) * 2002-10-25 2004-03-09 Dexcel Pharma Tech, Ltd Venlafaxine formulations
US20050191349A1 (en) * 2003-12-31 2005-09-01 Garth Boehm Galantamine formulations
WO2007025182A2 (fr) * 2005-08-26 2007-03-01 Bpsi Holdings, Inc. Compositions de medicament renfermant des matrices d'hypermellose a liberation commandee
US20100221335A1 (en) * 2007-08-31 2010-09-02 Daiichi Sankyo Company, Limited Sustained-release preparation and method for producing the same

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5602182A (en) * 1995-01-30 1997-02-11 American Home Products Corporation Taste masking pseudoephedrine HCL containing liquids
US20030190351A1 (en) * 2002-03-28 2003-10-09 Synthon Bv Extended release venlafaxine formulations
US6703044B1 (en) * 2002-10-25 2004-03-09 Dexcel Pharma Tech, Ltd Venlafaxine formulations
US20050191349A1 (en) * 2003-12-31 2005-09-01 Garth Boehm Galantamine formulations
WO2007025182A2 (fr) * 2005-08-26 2007-03-01 Bpsi Holdings, Inc. Compositions de medicament renfermant des matrices d'hypermellose a liberation commandee
US20100221335A1 (en) * 2007-08-31 2010-09-02 Daiichi Sankyo Company, Limited Sustained-release preparation and method for producing the same

Also Published As

Publication number Publication date
WO2012068076A2 (fr) 2012-05-24

Similar Documents

Publication Publication Date Title
MX2020011961A (es) Formas de dosis de liberacion controlada para substancias de farmaco de alta dosis, solubles en agua e higroscopicas.
NO20090554L (no) Farmasoytiske preparater av memantin
MX2008012731A (es) Tabletas de paracetamol de liberacion rapida.
WO2010127205A3 (fr) Formulations de combinaison de médicament à dose fixe
PH12015500823A1 (en) Modified release formulations for oprozomib
MX340188B (es) Elaboracion de granulos sin activos y tabletas que comprenden los mismos.
WO2010020856A3 (fr) Administration modulée de médicaments depuis un dispositif d’administration composite
WO2010092450A8 (fr) Composition pharmaceutique stable pour l'athérosclérose
IL215826A (en) Pharmaceutical preparation with delayed release, process of preparation of the preparation, use of the preparation for the preparation of pain medication and the pill containing it.
WO2011067667A3 (fr) Microcapsules de fexofénadine et compositions les contenant
PH12014502191A1 (en) Capsule disintegrable in large-intestine-specific manner
SI2729130T1 (en) Combined formulations of darunavir
WO2012053785A3 (fr) Pastilles à libération prolongée contenant du tacrolimus à titre de principe actif
PH12014501408A1 (en) Immediate release multi unit pellet system
WO2012092486A3 (fr) Formulations de benzimidazole à libération modifiée
WO2012052834A3 (fr) Système particulaire d'unités multiples comprenant du succinate de métoprolol
WO2012068076A3 (fr) Formulations pharmaceutiques contenant des médicaments solubles
WO2009084041A3 (fr) Compositions pharmaceutiques de dexibuprofène
WO2013018050A3 (fr) Système d'administration de médicaments à libération contrôlée et dissolution améliorée pour médicaments peu solubles dans l'eau
EP3648745A4 (fr) Composition pharmaceutique comprenant un comprimé sphéroïdal à unités multiples contenant de l'ésoméprazole et un sel de qualité pharmaceutique de celui-ci, et procédé de préparation de la composition pharmaceutique
PT2389070E (pt) Formulações desintegráveis de carbonato de lantânio
WO2009000473A3 (fr) Comprimés effervescents destinés à être inhalés
WO2011108882A3 (fr) Composition pharmaceutique pour la prévention ou le traitement de l'ostéoarthrite contenant du rébamipide en tant que principe actif
MX2017000384A (es) Forma de dosificacion en capsulas de succinato de metoprolol.
EP1949900A3 (fr) Formulation solide à libération contrôlée pour l'administration orale en tant que sachet monodose et son procédé de préparation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11841843

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11841843

Country of ref document: EP

Kind code of ref document: A2